The purpose of this study is to describe the population pharmacokinetic characteristics of piperacillin/tazobactam after intravenous administration in pregnant women during pregnancy and delivery, and to evaluate pharmacodynamic effectiveness and safety of piperacillin/tazobactam in pregnant women whose baby are at high risk of developing early-onset sepsis after birth.
Patients over 18 years old;
Pregnant women whose baby are at high risk of developing early-onset sepsis after birth have indications to use preventive or therapeutic antibiotics, and the antibiotics used are PIP/TAZO；
Patients and their families are fully aware of the research content and sign the informed consent form.
Intolerance or serious adverse reactions to antibiotic use;
Patients who stopped using PIP/TAZO more than 24 hours before delivery;
Receiving other systemic trial drugs;
There are other factors that the researchers think are not suitable for inclusion
The research population of this study is pregnant individuals whose baby at high risk of developing early-onset sepsis after birth.
Cohort
Prospective
Piperacillin Sodium and Tazobactam Sodium for Injection
DrugPiperacillin/Tazobactam, specification: 4g; 0.5g. Anti-infective therapy with piperacillin/tazobactam, specific regimen based on clinical practice, without intervention.
Clearance (L/h) of piperacillin/tazobactam
The mean population pharmacokintic parameter as well as its interindividual variability
Volume of Distribution (L) of piperacillin/tazobactam
The mean population pharmacokintic parameter as well as its interindividual variability
PD target attainment
PD target is defined as the time of free drug concentration beyond MIC during the dose interval
Adverse events
Drug-related adverse events and serious adverse events during the study.
Click on the lead sponsor to view all of their trials.
Shandong University
Lead sponsor
Shandong Provincial Hospital
Collaborator
